

Haematologica
HAEMATOL/2019/224196
Version 1
Six-packed antibodies punch better

Christoph Rader and Adrian Wiestner

Disclosures: Information on support received for work outside the submitted work: Adrian Wiestner reports research support from Pharmacyclics, Acerta Pharma, and Merck. Dr. Rader reports grants from the NIH during the conduct of the study; grants and personal fees from NBE-Therapeutics, Inc. (Basel, Switzerland), grants from Alnylam, Inc. (Cambridge, MA, USA), grants and personal fees from BlinkBio, Inc. (Jupiter, FL, USA), personal fees from Takeda, Inc. (Cambridge, MA, USA) and AbbVie, Inc. (Redwood City, CA, USA), non-financial support from Heidelberg Pharma, Inc. (Ladenburg, Germany), and other from T-CURX (Würzburg, Germany), outside the submitted work; in addition, Dr. Rader has U.S. Patent 10,035,848 issued (not licensed), U.S. Patent Application 20190055305 pending (not licensed), and numerous issued and pending patent families in the field of monoclonal antibodies targeting hematologic and solid malignancies, several of which are licensed to companies that pay royalties; none of Dr. Rader's issued and pending patents are licensed by Genmab.

Contributions: Adrian Wiestner and Christoph Rader jointly wrote the editorial.